APA (7th ed.) Citation

KG, S., NK, A., C, B., B, G., EH, J., RS, F., . . . JA, K. (2026). Patient-reported outcomes from the randomized ALICE trial evaluating the addition of atezolizumab to anthracycline-based chemotherapy in metastatic triple-negative breast cancer. Breast (Edinburgh, Scotland), 86, 104704. https://doi.org/10.1016/j.breast.2026.104704

Chicago Style (17th ed.) Citation

KG, Svalheim, Andresen NK, Bjerre C, Gilje B, Jakobsen EH, Falk RS, Naume B, Kaasa S, and Kyte JA. "Patient-reported Outcomes from the Randomized ALICE Trial Evaluating the Addition of Atezolizumab to Anthracycline-based Chemotherapy in Metastatic Triple-negative Breast Cancer." Breast (Edinburgh, Scotland) 86 (2026): 104704. https://doi.org/10.1016/j.breast.2026.104704.

MLA (9th ed.) Citation

KG, Svalheim, et al. "Patient-reported Outcomes from the Randomized ALICE Trial Evaluating the Addition of Atezolizumab to Anthracycline-based Chemotherapy in Metastatic Triple-negative Breast Cancer." Breast (Edinburgh, Scotland), vol. 86, 2026, p. 104704, https://doi.org/10.1016/j.breast.2026.104704.